The complicated urinary tract infections (cUTI) market is projected to expand steadily through 2036, driven by increasing antimicrobial resistance, higher rates of recurrent and hospital-acquired infections, and more patients with underlying conditions like diabetes and kidney disease. Recent FDA approvals of new drugs such as GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH, along with emerging therapies including Cefepime–taniborbactam and FOVISCU, are expected to enhance treatment options. These innovations target resistant Gram-negative bacteria, addressing a critical unmet need. The U.S. leads the market, with about 3.5 million diagnosed cases in 2024, and ongoing clinical trials suggest further advancements in oral and combination therapies to reduce reliance on intravenous antibiotics.
The recent approvals of new drugs by GSK and others highlight ongoing innovation in the treatment of complicated urinary tract infections. On Pluang, GSK shares are trading at USD 46.97 with a 1-day gain of 1.00% as of Oct 13, 2026 00:22 WIB. The company holds a market cap of $92.76 billion and offers a dividend yield of 3.91%, reflecting steady investor interest in its health sector developments.
